Sabby Management’s Antares Pharma, Inc. ATRS Stock Holding History

Sabby Management’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,016	Closed	-$329K	–	205
2017 Q3	$329K	Hold	1,016	–	–	0.02%	117
2017 Q2	$327K	Buy	+1,016	New	+$2.88K	0.02%	162
2016 Q2	–	Sell	-399	Closed	-$35K	–	350
2016 Q1	$35K	Sell	399 -467	-54%	-$452	﹤0.01%	288
2015 Q4	$105K	Sell	866 -1,876	-68%	-$2.61K	0.01%	297
2015 Q3	$466K	Buy	+2,742	New	+$5.38K	0.02%	298

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sabby Management's ATRS Position: Q3 2016 in Review

Sabby Management sold out of Antares Pharma, Inc. (ATRS) in Q3 2016, closing a stake of 424,100 shares — an estimated $445K sold.

Sabby Management first reported a position in ATRS in Q3 2015 and held it in 4 quarters. The position peaked at $1.23M in Q3 2015. 67 funds tracked by Wall St. Rank hold ATRS as of Q3 2016.

Sabby Management reported no remaining Antares Pharma, Inc. position as of Q3 2016 after selling out during the quarter.
Sabby Management sold 424,100 Antares Pharma, Inc. shares in Q3 2016, an estimated $445K.
Sabby Management first reported a position in Antares Pharma, Inc. in Q3 2015 and held it in 4 quarters.
Sabby Management's Antares Pharma, Inc. position peaked at $1.23M in Q3 2015.
67 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.